Patients and treatment protocols
This cohort included 111 newly diagnosed ALL pediatric patients with CDKN2A deletion.All patients were diagnosed and treated according to CCLG-ALL 2015 protocol[1] at Blood Disease Hospital of CAMS & PUMC between September 2016 and December 2019.The following patients were not included in this cohort:a .patients who diagnosed as mature B-lineage ALL or mixed-phenotype acute leukemia (MPAL)(excluding ALL with myeloid antigen expression);b .patients developed from chronic myeloid leukemia blast crisis(CML-BP),another cancer or immunodeficiency disease;c .patients who had undergone chemotherapy or radiation in three months(excluding emergency radiotherapy to relieve the oppression symptoms);d .patients who used to treat glucocorticoid no less than7 days between one week to one month before enrollment.The immunophenotype was distinguished by a panel of monoclonal antibodies including markers for B-lineage cells(CD10,CD19,TdT,cyμ,sIgM,CD20,cyCD22,CD22,cyCD79a),T-lineage cells(CD1a,CD2,CD3,CD4,CD5,CD7,CD8,TCRαβ,TCRγδ,cyCD3)or myeloid cells(CD11b,CD13,CD14,CD15,CD33,CD41,CD61,CD64,CD65,CD71,GPA,cyMPO).
The protocols described in this study were approved by the Ethics Committee,Institute of Hematology & Blood Disease Hospital,CAMS & PUMC.All patients or their legal guardians signed written informed consent before treatment.